Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
- PMID: 6703192
- DOI: 10.1097/00000478-198403000-00001
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Abstract
A series of 43 adrenocortical tumors was analyzed using nine histologic features. Mitotic activity, especially with atypical forms, and venous invasion correlated best with metastasizing or recurring tumors; however, no single criterion was useful alone. The combination of the following nine criteria was most useful in distinguishing malignant from benign tumors: nuclear grade III or IV; mitotic rate greater than 5/50 high-power fields; atypical mitoses; clear cells comprising 25% or less of the tumor; a diffuse architecture; microscopic necrosis; and invasion of venous, sinusoidal, and capsular structures. None of the 24 tumors with two or less of these criteria metastasized or recurred, while all but one of the 19 tumors with four or more of these criteria either recurred or metastasized.
Similar articles
-
Pathologic features of prognostic significance in adrenocortical carcinoma.Am J Surg Pathol. 1989 Mar;13(3):202-6. doi: 10.1097/00000478-198903000-00004. Am J Surg Pathol. 1989. PMID: 2919718
-
Adrenocortical oncocytic tumors: report of 10 cases and review of the literature.Int J Surg Pathol. 2004 Jul;12(3):231-43. doi: 10.1177/106689690401200304. Int J Surg Pathol. 2004. PMID: 15306935
-
Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients.Am J Surg Pathol. 2003 Jul;27(7):867-81. doi: 10.1097/00000478-200307000-00001. Am J Surg Pathol. 2003. PMID: 12826878
-
Adrenocortical Oncocytic Carcinoma: A Case Report and Review of the Histopathologic Diagnostic Criteria.Turk Patoloji Derg. 2016;32(3):211-5. doi: 10.5146/tjpath.2014.01250. Turk Patoloji Derg. 2016. PMID: 27562395 Review. English.
-
Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma.Endocr Pathol. 2006 Winter;17(4):345-54. doi: 10.1007/s12022-006-0006-0. Endocr Pathol. 2006. PMID: 17525483 Review.
Cited by
-
Clinical and Pathological Predictors of Death for Adrenocortical Carcinoma.J Endocr Soc. 2024 Jan 8;8(4):bvad170. doi: 10.1210/jendso/bvad170. eCollection 2024 Feb 19. J Endocr Soc. 2024. PMID: 38384443 Free PMC article.
-
High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study.Int J Mol Sci. 2023 Nov 21;24(23):16573. doi: 10.3390/ijms242316573. Int J Mol Sci. 2023. PMID: 38068896 Free PMC article.
-
Prognosis of Adrenal Oncocytic Neoplasms (AONs): Literature Review of 287 Cases and Presentation of the Oldest Patient.J Clin Med. 2023 Nov 4;12(21):6925. doi: 10.3390/jcm12216925. J Clin Med. 2023. PMID: 37959390 Free PMC article. Review.
-
Durable response to pembrolizumab in microsatellite instability-high advanced adrenocortical carcinoma.IJU Case Rep. 2023 Sep 21;6(6):382-385. doi: 10.1002/iju5.12628. eCollection 2023 Nov. IJU Case Rep. 2023. PMID: 37928286 Free PMC article.
-
Advances in translational research of the rare cancer type adrenocortical carcinoma.Nat Rev Cancer. 2023 Dec;23(12):805-824. doi: 10.1038/s41568-023-00623-0. Epub 2023 Oct 19. Nat Rev Cancer. 2023. PMID: 37857840 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources